The Minneapolis-based startup will use the National Institute of Mental Health grant toward further development of its wearable device that treats impulsive behaviors.
Nothing has been confirmed yet, but a report from Axios indicates the Minnesota-based insurance giant will buy Washington-based pharmacy company Genoa Health.
Company also inks deal to co-develop laser device to treat arterial disease.
The Eden Prairie-based company specializing in brain issue detection is in the midst of a hefty fundraising campaign. The first investment was obtained early this month, with more than $9 million more to go toward its target.
Miromatrix, Superior Organoid, and MNPHARM each landed $100,000 regenerative medicine awards.
The company is working towards clinical trials for its implantable kidney and liver products.
A collaboration between Mayo and Exact Sciences is yielding accurate blood DNA tests for treatable cases.
Noaber Foundation led a $1.5 million venture round for the digital health platform.
The move from California to Minnesota comes as the chronic lower back pain device maker has wrapped a $58 million fundraising round.
The deal continues a string of transactions by Bio-Techne over the last five years and marks its foray into the diagnostics area of cancer medicine.
The possible deal sent Boston Scientific’s shares up about 7.5 percent and Stryker’s down by more than 5 percent.
Magenta Therapeutics looks to expand the amount of stem cells for marrow transplants.
The new printer has been proven capable of printing out skin cells to repair wounds in tests on mice.
Cytox Ltd. will use bio-samples from Mayo to develop an algorithm predicting genetic vulnerability.
Partnering company MRI Interventions says the next step will be filing a 510(k), which will come in the third quarter.
The institute will focus on treatments for “cellular senescence” to slow the aging process.
It will play a key role in the U.S. “All of Us” effort to advance individualized medicine.
IPO documents reveal potential of clinic’s collaboration with Evelo Biosciences.
Powered by the Mayo Clinic’s AI, research claims it can read blood potassium with a touch.
Shares of the Maple Grove sleep apnea device maker were up more than 50 percent on its opening day.
The money will go toward advancing the company’s efforts to treat acute decompensated heart failure.
Medicool Technologies is looking to halt atrial fibrillations painlessly with a new, novel implant.
Method uses newly-discovered molecular targets to make deadly tumors more vulnerable.
Developer of PetChatz, a pet-to-human connection device, moves to address a healthcare issue with new product Ōmcare.
San Francisco anti-aging firm seeks $85 million for clinical trials using Mayo intelligence.
The medical device giant expects the deal could one day be huge, entering it into a market valued between $500 million and $2 billion.
Use of ‘liquid biopsies’ to track disease progression found to be feasible.
The sleep apnea device maker is the sixth company out of Minnesota this year to register for an initial public offering.
The university’s Clinical and Translational Science Institute, which helps support research in various behind-the-scenes ways, awarded funds from the National Institutes of Health.
The funds will aid in commercialization of wearable technology geared toward improving balance and preventing falls.